# Study Evaluating the Impact of the 13-valent Pneumococcal Conjugate Vaccine (13vPnC) in Alaskan Native Children.

> **NCT00743652** · PHASE3 · COMPLETED · sponsor: **Pfizer** · enrollment: 373 (actual)

## Conditions studied

- Pneumococcal Disease
- 13-valent Pneumococcal Vaccine

## Interventions

- **BIOLOGICAL:** 13-valent Pneumococcal Conjugate Vaccine
- **BIOLOGICAL:** 13-valent Pneumococcal Conjugate Vaccine
- **BIOLOGICAL:** 13-valent Pneumococcal Conjugate Vaccine
- **BIOLOGICAL:** 13-valent Pneumococcal Conjugate Vaccine
- **BIOLOGICAL:** 13-valent Pneumococcal Conjugate Vaccine

## Key facts

- **NCT ID:** NCT00743652
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-01
- **Primary completion:** 2010-09
- **Final completion:** 2010-09
- **Target enrollment:** 373 (ACTUAL)
- **Last updated:** 2012-03-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00743652

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00743652, "Study Evaluating the Impact of the 13-valent Pneumococcal Conjugate Vaccine (13vPnC) in Alaskan Native Children.". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT00743652. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*